Adenocarcinoma Clinical Trial
Official title:
A Prospective, Observational, Multicenter Study on Biomarkers for Predicting the Efficacy and Toxicities of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Based on Tissue and Plasma Exosome RNA
Backgrounds: A multicenter randomized phase III trial (NCT02605265) proved that adding
irinotecan guided by UGT1A1 to capecitabine-based neoadjuvant chemoradiotherapy significantly
increases complete tumor response. The treatment toxicities were increased but tolerable.
Purposes: This study aims to identify the predictive biomarkers (from patients' tumor biopsy
samples and peripheral blood samples before neoadjuvant therapy) for predicting the response
and toxicities to neoadjuvant therapy to stratify patients and optimize treatment strategy.
OBJECTIVES:
Primary:
- Establish a predictive model for response based on tissue RNA and plasma exosome RNA
- Establish a predictive model for toxicities based on tissue RNA and plasma exosome RNA
Secondary:
- Internal validation of the established predictive models
- External validation of the established predictive models
OUTLINE:
-Treatment: Patients receive neoadjuvant therapy and surgery per the protocol. Samples
collection Tumor tissue and peripheral blood will be collected prior to neoadjuvant therapy.
-Grouping: Response: Patients will be dichotomized into two groups based on the TRG. TRG of
0-1 is defined as good response. TRG of 2-3 is defined as poor response.
Toxicities: Patients will be dichotomized into two groups based on the grade of AEs. No grade
3-4 toxicities occurs during neoadjuvant therapy is defined as light toxicities. Grade 3-4
toxicities occur during neoadjuvant therapy is defined as heavy toxicities.
-Predictive Model Construction: Using RNA sequencing method to obtain the whole genome
transcription profiles of the tumor tissue and plasm exosome RNA. Compare the gene expression
differences between the two response groups and the two toxicity groups. Predictive models of
response and toxicities are constructed.
-Internal Validation: Patients treated at Fudan University Shanghai Cancer Center (N=50) per
the protocol will be enrolled as the internal validation cohort. Samples of tissue and plasm
will be collected and analyzed. The performance of the model will be evaluated by the
correlation of the predicted response/toxicities and the actual response/toxicities.
-External Validation: Patients treated at Liao'ning Cancer Hospital & Institute (N=50) and
Harbin Medical University Cancer Hospital (N=50) per the protocol will be enrolled as two
external validation cohorts. Samples of tissue and plasm will be collected and analyzed. The
performance of the model will be evaluated by the correlation of the predicted
response/toxicities and the actual response/toxicities.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05678218 -
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
|
||
| Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
| Withdrawn |
NCT05325164 -
Methadone for 'Adenocarcinopathic' Pain Treatment
|
Phase 3 | |
| Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT02125240 -
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
|
Phase 3 | |
| Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
| Completed |
NCT02454647 -
Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients
|
N/A | |
| Completed |
NCT01579721 -
Prospective Randomized Study of SILS Versus CLS for Rectal Cancer
|
Phase 4 | |
| Completed |
NCT01206530 -
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01148082 -
School Response to Families Who Have Children With Cancer
|
N/A | |
| Completed |
NCT00548548 -
A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
|
Phase 3 | |
| Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00377936 -
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
| Completed |
NCT00183859 -
Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan
|
Phase 1 | |
| Recruiting |
NCT01930864 -
Metformin Plus Irinotecan for Refractory Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT02498860 -
Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung
|
Phase 2 | |
| Terminated |
NCT01441128 -
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
| Recruiting |
NCT02133196 -
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 |